68 results about "Agglutinin" patented technology

The invention discloses application of citrullinated endolectin-1 polypeptide in preparation of rheumatoid arthritis diagnosis products, and belongs to the technical field of rheumatoid arthritis diagnosis. The amino acid sequence of the citrullinated endolectin-1 polypeptide is GD-Cit-WSSQQGSKAVYPE, and the amino acid sequence of the citrullinated endolectin-1 polypeptide is GD- The product is used for detecting the content of the anti-citrullinated endolectin-1 polypeptide antibody in a biological sample of a patient, and the antibody level is remarkably different from that of normal healthy people and other common rheumatism immune disease patients easily confused with rheumatoid arthritis in the body of an RA patient. The kit has good sensitivity for common RA, RA with normal ESR and CRP, and anti-CCP antibody / RF negative RA patients, and has good supplementary diagnostic value for RA diagnosis.

The invention discloses a fruit and vegetable exosome extraction method based on ligand fishing. The fruit and vegetable exosome extraction method comprises the following steps: suspending amino-functionalized Fe3O4 (at) SiO2 nanoparticles in a glutaraldehyde solution, and adding activated agglutinin to obtain Fe3O4 (at) SiO2-agglutinin nanoparticles; adding a glutaraldehyde solution into agarose gel to obtain a size exclusion chromatographic column filler; the method comprises the following steps: dispersing Fe3O4 (at) SiO2-lectin nanoparticles in a PBS buffer solution to obtain a uniform suspension, adding the uniform suspension into a size exclusion chromatographic column filler to obtain a uniform slurry, filling the size exclusion chromatographic column with the uniform slurry, and flushing with the buffer solution to form a magnetic bead stationary phase; and loading fruit and vegetable supernatant into a size exclusion chromatographic column, passing through the magnetic bead stationary phase, cleaning residual impurities combined on the exosome-magnetic bead compound by using a buffer solution, and dissociating the exosome from the magnetic beads by using a competitive eluent of the exosome to obtain the high-purity fruit and vegetable exosome. The problem that an existing exosome extraction method is difficult to meet the requirements of high efficiency, simplicity, high purity and high activity at the same time is solved.

Disclosed herein are anti-Galectin-9 antibodies and methods of using in modulating (e.g., increasing) immune responses in a subject, either taken alone or in combination with an immune checkpoint inhibitor, such as a PD-1 inhibitor.

The application provides a galactoside agglutinin 10 (Gal10) crystal and a preparation method and prepared antibody IgY and a pharmaceutical preparation thereof, and belongs to the technical field of medicines. The application uses the galactoside agglutinin 10 crystal as an antigen to prepare an egg yolk neutralizing antibody IgY capable of dissolving the Gal10 crystal, has the effects of improving rhinitis or asthma of a patient, preventing and treating rhinitis and asthma, and is safe, has no side effects, has a long-lasting curative effect, and has no drug resistance, thereby providing a safe, simple, hygienic, effective, economic and personalized treatment mode for prevention and treatment of rhinitis and asthma, and having a high market value.

The present disclosure relates to the field of RNAs for the prevention or treatment of various infectious agents. In particular, the present disclosure relates to methods and agents for vaccination against coronavirus infection, influenza infection and / or RSV infection and induction of effective coronavirus, influenza virus and / or RSV antigen-specific immune responses, such as antibodies and / or T cell responses. Specifically, in one embodiment, the disclosure relates to a method comprising administering to a subject (i) a bivalent RNA vaccine encoding a peptide or protein comprising an epitope of SARS-CoV-2 spike protein (S protein), and (ii) a tetravalent RNA vaccine encoding a peptide or protein comprising an epitope of hemagglutinin (HA), the present invention relates to a method for inducing an immune response in a subject against a coronavirus S protein, in particular an S protein of SARS-CoV-2, and an influenza protein, in particular an HA protein of influenza A and B viruses.

The application discloses a fucose glycoprotein detection kit, a preparation method thereof and a fucose glycoprotein color developing method. First, a liquid sample is dropped on the surface of the kit, and the sample and test paper are infiltrated through a sample inlet. Under the action of transverse flow force, the sample flows to an observation window along a hydrophilic test paper. The glycoprotein containing alpha 1,2-fucose in the sample is combined with agglutinin 1, and the rest of the sample continues to flow to the next layer of test paper. Then, the glycoprotein containing alpha 1,3-fucose is combined with agglutinin 2, and the rest of the sample flows to the third layer and is combined with agglutinin 3 containing alpha 1,6-fucose glycoprotein. All the combined fucose glycoproteins are combined with agglutinin biotin through their antibodies, and horseradish peroxidase is used for labeling color development, so that quantitative detection of the fucose glycoprotein in the sample is realized. The method has important significance for studying the changes of different connection fucose glycoproteins in cells and body fluids in diseases.

The present invention relates to a chimeric influenza virus hemagglutinin (HA) polypeptide comprising one or more stem domain sequences fused to one or more globular head domain sequences, each of the one or more stem domain sequences having at least 60% homology to a stem domain consensus sequence of an H1 subtype HA (H1 HA) and / or an H5 subtype HA (H5 HA), each of the one or more globular head domain sequences having at least 60% homology to a globular head domain consensus sequence of an H1 subtype HA (H1 HA) or an H5 subtype HA (H5 HA).

To provide an osteoclast fusion inhibitor that is highly effective and has few side effects. [Solution] An osteoclast fusion inhibitor containing an anti-galectin-3 neutralizing antibody as an active ingredient.

The invention discloses a universal magnetic nano-enzyme probe for detecting bacteria and viruses, a preparation method, a reagent strip and application, the universal magnetic nano-enzyme probe comprises magnetic Fe3O4 nano-particles and multiple layers of cationic polymer strong positive electricity interlayers loaded on the surfaces of the magnetic Fe3O4 nano-particles, the magnetic Fe3O4 nano-particles serve as inner cores, and the magnetic Fe3O4 nano-particles serve as outer cores. A cationic polymer is used as a connecting layer to adsorb multi-layer small gold iridium alloy nanoparticles (Au (at) Ir), the surfaces of the multi-layer small gold iridium alloy nanoparticles are coupled with wheat germ agglutinin protein molecules, Fe3O4 nanoparticles provide magnetic response ability, and the multi-layer Au (at) Ir provides colorimetric signals, catalytic sites and binding sites. Wheat germ agglutinin (WGA) provides the ability of a label to capture pathogens in a broad spectrum, the Fe-DAu-Ir-WGA probe is combined with an LFA technology, colorimetric signal reading is carried out through ImageJ software, and efficient and ultra-sensitive quantitative detection of multiple pathogens is achieved.

According to the application of a reagent for detecting the biomarker in preparation of a xerophthalmia diagnosis and typing detection reagent, the galectin-9 plays an important role in the occurrence and development process of the xerophthalmia, the expression level of the galectin-9 has a certain correlation with the severity of the xerophthalmia, and the galectin-9 is expected to be used as the biomarker for diagnosis and treatment of the xerophthalmia and can be used for preparing the xerophthalmia diagnosis and typing detection reagent. By detecting the expression condition of Galectin-9 in tears, early and accurate diagnosis of the dry eye and quantitative evaluation of the disease degree are achieved, in addition, Galectin-9 expressed on T cells plays an important role in immune inflammation of the dry eye, ocular surface damage of the dry eye can be relieved by locally intervening Galectin-9 through conjunctiva, and Galectin-9 serves as a novel potential target and has a good application prospect. A new way is opened up for diagnosis and treatment of xerophthalmia, a therapeutic drug or an intervention means developed for Galectin-9 can regulate immune response, inhibit inflammatory response, improve tear secretion and the like from the etiological level, and an existing xerophthalmia treatment mode is expected to be changed, so that the treatment effect is improved, the prognosis of a patient is improved, and the clinical application prospect is broad. The application prospect in the field of diagnosis and treatment of the xerophthalmia is wide, and a certain significance is achieved for improving the overall prevention and treatment level of the xerophthalmia.

Provided herein are methods and compositions for suppressing a foreign body reaction, such as an implant-associated inflammation in a subject, by using an anti-Galectin-3 antibody. Such methods and compositions can be used in various areas applications where an implant is introduced, such as in brain-computer interface (BCI).

The application belongs to the field of biosensors, and provides a construction method and application of an electrochemical biosensor for quantifying AFP-L3% (AFP-L3 / AFP), and the specific process is as follows: Au@UiO-66 nanocomposites are obtained by using a hydrothermal method and an immersion reduction method, TCEP can open S-S in alpha-fetoprotein to obtain sulfydryl (-SH) and connect to Au@UiO-66, in-situ synthesis of AFP aptamer-copper clusters (Apt-CuNCs) is carried out by using DNA as a template, Apt-CuNCs are used to recognize total AFP, the content of total AFP is determined by using the generated Cu electrochemical signal, then, the Apt-CuNCs are subjected to enzymatic cleavage and stripping by using exonuclease I, alpha-fetoprotein heterogeneity (AFP-L3) is labeled by using lentil agglutinin (LCA) functionalized silver nanoparticles LCA@AgNPs, the content of AFP-L3 is determined by using the generated Ag electrochemical signal, and AFP-L3% can be calculated by combining the data of the two, and the electrochemical biosensor constructed by the method can be used for determining AFP-L3% in human serum.

The invention provides humanized monoclonal antibodies against Gal9, and method of using the antibodies to treat cancer, including combination therapy with antagonists of the PD-1 / PD-L1 immune checkpoint.

The invention relates to a preparation method and application of a probe based on wheat germ lectin. The probe is provided with a core-shell structure, and the core-shell structure is provided with a core and a shell wrapping the outer surface of the core. The core of the core-shell structure is Fe3O4 nanoparticles; the shell comprises a first cationic polymer layer, a gold nanoparticle layer, a second cationic polymer layer, a first quantum dot layer, a third cationic polymer layer, a second quantum dot layer and a wheat germ agglutinin layer which are sequentially coated from the outer surface of the core to the outside. The probe has relatively strong magnetic response capability, colorimetric signals, fluorescence signals and capability of capturing various virus glycoproteins; the MAuDQD-coated WGA-LFA method based on the probe provided by the invention is relatively wide in target detection object range, relatively high in detection sensitivity, relatively high in accuracy and relatively short in detection time.

Disclosed herein are combination therapies for treating hematological malignancies (e.g., acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS)) using an antibody that binds human galectin-9 (anti-Gal9 antibody, e.g., G9.2-17) and one or more chemotherapeutic agents, e.g., a Bcl2 inhibitor such as venetoclax, a hypomethylating agent (HMA), or a combination thereof.

The invention discloses a multi-copy expression construction method of an insecticidal fusion peptide U10-MYRTX-Mri1a-GNA with bacteriostatic activity in pichia pastoris, which comprises the following steps: 1, carrying out reverse PCR (Polymerase Chain Reaction) on a plasmid pGAPZalpha A, introducing a Hind III restriction enzyme cutting site to obtain a plasmid pGAPZalpha A-Hind III, 2, constructing a fragment containing a U10-MYRTX-Mri1a gene, and 3, carrying out multi-copy expression on the fragment containing the U10-MYRTX-Mri1a gene to obtain the insecticidal fusion peptide U10-MYRTX-Mri1a gene. The method comprises the following steps: 1, constructing a U10-MYRTX-Mri1a gene fragment, 2, constructing a U10-MYRTX-Mri1a gene fragment, 3, introducing a GGGSAAA linker and a snowflake agglutinin (GNA)-6 * His label to the C end of the U10-MYRTX-Mri1a gene fragment, 4, constructing a multi-copy expression vector pGAPZalpha A-HindIII-Mira1-GNA * 3, 5, preparing a pichia pastoris competent cell X33, and 6, carrying out electrochemical conversion to obtain a genetically engineered bacterium X33-pGAPZalpha A-HindIII-Mira1-GNA * 3. According to the invention, a linearized plasmid is transferred to pichia pastoris X33, so that a genetically engineered bacterium for expressing the fusion peptide U10-MYRTX-Mri1a-GNA is obtained.

Provided herein are antibodies that target Galectin-3. Such antibodies are used in methods of treating epilepsy and related neurological disorders, such as Alzheimer's disease (AD) and Parkinson's disease (PD).

The invention discloses a kit for detecting plasma IgG glycosylation level and a detection method thereof, and relates to the technical field of biological detection.Plasma IgG is specifically captured through protein A, four biotinylation lectins are combined, sialylation, galactosylation, fucosylation and mannosylation levels of IgG can be synchronously and quantitatively detected, a standardized ELISA system is established, and the kit is used for detecting the plasma IgG glycosylation level. Operation is easy and convenient, repeatability is good, and the problem that multi-dimensional simultaneous detection cannot be achieved in the prior art is solved. The kit is low in cost, does not need complex instruments, is suitable for large-scale clinical popularization, and fills the market blank of commercial IgG glycosylation ELISA kits. Clinical samples of colorectal cancer prove that patients and healthy people can be effectively distinguished, in-vitro risk assessment can be realized by combining a column diagram model, the detection efficiency is excellent, and the method can be expanded to be applied to assessment and monitoring of various tumor and inflammation related diseases, and has high clinical value.

The invention relates to a double-probe detection kit for detecting escherichia coli O157: H7 and a preparation method of the double-probe detection kit, and belongs to the technical field of food safety. The double-probe detection kit consists of a magnetic separation probe reagent and a copper-manganese double-metal nano-enzyme probe reagent which are independently packaged. The magnetic separation probe reagent is a concanavalin agglutinin A modified magnetic bead, and is used for specifically binding escherichia coli O157: H7 in a meat product detection sample and carrying out separation and enrichment treatment; the bimetallic nano-enzyme probe reagent is copper-manganese bimetallic nano-enzyme modified by a nucleic acid aptamer, and is used for specifically combining with the escherichia coli O157: H7 subjected to separation and enrichment treatment and generating an escherichia coli O157: H7 concentration dependent colorimetric signal and a fluorescence signal. According to the invention, mutual verification is carried out between dual-mode signals, so that the accuracy of a detection result is improved; the detection time is within 1.5 h, and the method has good specificity for common type strains. The invention provides a design thought for the development of detection sensors for escherichia coli O157: H7 and other meat-derived pathogenic bacteria.

The present invention provides compositions used for the treatment and / or prevention of protein aggregation disorders. [Solution] Proteopathy encompasses a wide range of ailments, including neurodegenerative diseases (e.g., polyglutamine diseases such as huntingtin in Alzheimer's disease, Parkinson's disease, and Huntington's disease, and prion diseases); amyloidosis of other non-neuronal proteins (especially I1-antitrypsin, immunoglobulin light and heavy chains, lactadherin, apolipoprotein, gelzolin, lysozyme, fibrinogen, atrial natriuretic factor, keratin, lactoferrin, and β-2 microglobulin, etc.); sickle cell disease; cataracts; cystic fibrosis; retinitis pigmentosa; and nephrogenic diabetes insipidus. Administration of sulfatase inhibitors is generally suitable for treating and / or preventing protein toxicity associated with proteopathy. Therefore, the present invention provides compositions comprising sulfatase inhibitors for the treatment of proteopathy.

The present application relates to a kind of agglutinin joint targeting peptide modified nanosphere and its preparation method and application, belong to the biomedicine technical field.To solve the problem that the existing drug delivery system is difficult to have the integration of nasal brain barrier breakthrough, nasal long-term retention, brain lesion targeting, broad-spectrum drug loading and high biological stability, the present application provides a kind of agglutinin joint targeting peptide modified nanosphere, including polymer matrix core, biomimetic cell membrane shell and double-ligand functionalization surface crown layer in turn from inside to outside.The nanosphere of the present application can prolong the nasal retention time and efficiently penetrate the nasal mucosa barrier by relying on the synergistic effect of core-shell-crown three-layer structure, realize transnasal brain and lesion precise targeting, improve drug delivery efficiency and efficacy, and reduce toxic side effects.The nanosphere of the present application has a wide range of drug loading spectrum, suitable for the drug demand of various central nervous system diseases, and has excellent clinical transformation value and application prospect.

The invention belongs to the technical field of antivirus, and particularly discloses a siniperca chuatsi frog iridovirus oral composite vaccine and a preparation method thereof.The composite vaccine comprises an antigen core, a mucous membrane penetrating layer, a pH sensitive protective shell layer and a targeted modification layer, and the antigen core is formed by compounding a siniperca chuatsi frog iridovirus inactivated vaccine and an immunologic adjuvant; the mucous membrane penetrating layer is a pegylated chitosan-sodium alginate compound; the pH sensitive protective shell layer is a poly (beta-amino ester)-trehalose copolymer, and the targeted modification layer is wheat lectin. According to the siniperca chuatsi and frog iridovirus oral compound vaccine and the preparation method thereof, the technical problems that oral vaccines are easily degraded by digestive enzymes in aquatic animal bodies and the mucous membrane absorption efficiency is low are solved through the multi-layer structural design, the immune protection effect of the vaccines is remarkably improved, and the preparation method is simple and controllable and suitable for large-scale production.

Methods, systems, and kits are provided for standardizing lectin reagents and measuring galactose-deficient IgA1 (Gd-IgA1) as a biomarker for IgA nephropathy. The invention includes a method for standardizing test batches of lectin reagents by comparing binding activity to reference batches using calibration standards, with acceptance criteria based on analytical recovery within thresholds. A stabilized reference standard comprising enzymatically modified or recombinantly produced Gd-IgA1 exhibits parallelism with natural serum samples and enables reproducible quantification across runs. The invention further provides a lectin-based ELISA assay kit for quantitative measurement of Gd-IgA1 in biological samples, particularly serum, using standardized N-acetylgalactosamine (GalNAc)-specific lectins such as biotinylated Helix pomatia agglutinin (HPA) or Helix aspersa agglutinin (HAA). Clinical applications include diagnosing IgA nephropathy, risk stratification, monitoring disease progression, assessing treatment response, and screening kidney transplant donors. The standardization methodology is broadly applicable to validating binding reagents for detecting diverse biomarkers, peptides, and proteins in diagnostic assays.

The invention discloses ulva agglutinin as well as an extraction method and application thereof. The extraction method comprises the following steps: S1, grinding dried ulva into ulva powder; s2, uniformly mixing the ulva powder with a NaCl-containing phosphate buffer solution, extracting ulva agglutinin by an ammonium sulfate precipitation method after ultrasonic-assisted extraction, so as to prepare an ulva agglutinin crude extract; and S3, purifying the ulva agglutinin crude extract by adopting an AKTA avat25 protein purification system, so as to obtain the ulva agglutinin. The ulva agglutinin has high sensitization, an RBL-2H3 cell model is established, and the sensitization of the ulva agglutinin is evaluated through the influence of the ulva agglutinin on the cell morphology or the cell histamine release rate. By combining ammonium sulfate precipitation with ion exchange chromatography, the purity of the ulva agglutinin is improved and is obviously superior to that in the prior art, and the method is more efficient and higher in purity.

The present invention provides a pharmaceutical composition capable of accelerating the regeneration rate of damaged areas in nerves. [Solution] A pharmaceutical composition for promoting nerve regeneration, comprising (A) a hyaluronic acid derivative into which a cholesteryl group has been introduced, (B) one or more factors selected from the group consisting of secretory sialic acid-binding immunoglobulin-like lectin-9 and monocyte chemotactic factor-1, and (C) a cell adhesion material derived from collagen; the average molecular weight of the hyaluronic acid derivative into which the cholesteryl group has been introduced is 5,000 or more and 50,000 or less; and a method for promoting nerve regeneration, comprising contacting any of the pharmaceutical compositions with a damaged site in nerve tissue.

This invention relates to a comprehensive evaluation method for the quality of Pinellia ternata and a method for constructing a fingerprint spectrum of Pinellia ternata. The method includes: processing Pinellia ternata to obtain a test solution; preparing a reference solution containing guanosine, phenylalanine, VGTNY, tryptophan, LFSG, apigenin-6-C-arabinose-8-C-galactoside, PWVPG, NIPF, and VIYGPSVF; injecting the test solution and the reference solution separately into a liquid chromatography-mass spectrometry (LC-MS) instrument, and obtaining the fingerprint spectrum of the Pinellia ternata using LC-MS. A method for determining the content of toxic components calcium oxalate needle crystals and lectin protein is also established. The comprehensive evaluation method for the quality of Pinellia ternata provided by this invention comprehensively improves the evaluation standards for Pinellia ternata, ensuring the effectiveness and safety of Pinellia ternata in clinical use.

The utility model discloses a donkey-hide gelatin powder particle mixing and packaging device which comprises a bottom plate, the upper surface of the bottom plate is fixedly connected with an annular sliding rail, the annular sliding rail is connected with a plurality of electric sliding blocks in a sliding mode, the upper surfaces of the electric sliding blocks are fixedly connected with a containing plate, and the upper surface of the bottom plate is fixedly connected with a mixing and filling station. The upper surface of the bottom plate is fixedly connected with a sealing station, a detection station, a discharging station and a feeding station, the detection station comprises a supporting frame, the inner side face of the supporting frame is fixedly connected with a hydraulic cylinder, and the output end of the hydraulic cylinder is fixedly connected with a push rod. Through cooperation of the supporting frame, the hydraulic cylinder, the push rod and the extrusion roller, the packaging bag can be extruded, whether air leakage exists or not can be checked in an auxiliary mode, air leakage caused by improper sealing or material defects can be effectively reduced, and therefore the production quality is guaranteed.

The invention relates to a lectin chip for predicting colorectal cancer immunotherapy sensitivity and a preparation method and application thereof, and belongs to the technical field of tumor therapy. According to the chip disclosed by the invention, three specific agglutinin probes are fixed on the surface of a solid-phase carrier in a dot matrix manner, and combined detection of at least three carbohydrate chains in human serum is realized by coating three specific agglutinin probes; the solid-phase carrier is a 14-hole three-dimensional modified glass slide and is used for fixing specific lectin as a probe; and the three specific lectin probes are respectively PHA-E, SNA-I and SSA. The lectin chip can be used for predicting colorectal cancer immunotherapy sensitivity.

The present application relates to the field of food technology, and specifically discloses a composition for reducing gastroesophageal reflux in individuals, a preparation method and application thereof. The composition for reducing gastroesophageal reflux in individuals comprises lactadherin, medium-long chain triglyceride, human milk oligosaccharide and immunoglobulin G. The present application constructs a multi-target synergistic intervention mechanism combining physical protection, secretion regulation and tissue repair through the compounding of four core components, which can comprehensively block the occurrence and development of gastroesophageal reflux. Lactadherin constructs a physical barrier to reduce the risk of reflux dynamics from the source; MLCT precisely regulates gastric acid secretion, reducing chemical stimulation; HMO compound IgG strengthens the mucosal immune barrier and promotes damage repair. The above composition is applied to products for reducing gastroesophageal reflux in individuals, and multi-target synergistic effect is achieved, realizing the whole-chain closed-loop intervention from prevention, relief to repair, and significantly improving the clinical improvement effect.